GM-CSF and low-dose araC treatment of AML in prolonged hypoplasia with residual leukemic cells after induction chemotherapy
Yonsei Medical Journal
;
: 91-96, 1994.
Article
in English
| WPRIM
| ID: wpr-171806
ABSTRACT
We describe a case with acute myelogenous leukemia (AML; M2) who developed prolonged marrow hypoplasia with residual leukemic blasts and recurrent infections after induction chemotherapy. He was treated successfully with a sequential treatment of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and low-dose cytosine arabinoside (LD AraC). To the best of our knowledge this is the first reported case of a successful treatment of a patient with AML, who showed prolonged markedly hypocellular bone marrow with significant residual leukemic cells after induction chemotherapy, with a sequential treatment of GM-CSF and LD AraC.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Bone Marrow Diseases
/
Leukemia, Myeloid, Acute
/
Granulocyte-Macrophage Colony-Stimulating Factor
/
Cytarabine
/
Middle Aged
Limits:
Humans
/
Male
Language:
English
Journal:
Yonsei Medical Journal
Year:
1994
Type:
Article
Similar
MEDLINE
...
LILACS
LIS